Valuation: Veracyte, Inc.

Capitalization 2.47B 2.1B 1.95B 1.83B 3.42B 230B 3.49B 22.85B 8.94B 110B 9.27B 9.07B 393B P/E ratio 2026 *
34.2x
P/E ratio 2027 * 28.6x
Enterprise value 1.95B 1.66B 1.54B 1.45B 2.69B 181B 2.75B 18.01B 7.05B 86.97B 7.31B 7.15B 310B EV / Sales 2026 *
3.38x
EV / Sales 2027 * 2.79x
Free-Float
99.23%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week-3.60%
Current month-3.48%
1 month-4.22%
3 months-26.05%
6 months-10.66%
Current year-26.15%
1 week 30.56
Extreme 30.56
34.08
1 month 29.46
Extreme 29.455
34.18
Current year 29.46
Extreme 29.455
46.76
1 year 22.61
Extreme 22.61
50.71
3 years 18.61
Extreme 18.61
50.71
5 years 14.85
Extreme 14.85
57.97
10 years 4.81
Extreme 4.81
86.03
Manager TitleAgeSince
Chief Executive Officer 56 01/06/2021
Director of Finance/CFO 48 19/07/2021
Chief Tech/Sci/R&D Officer 40 24/03/2026
Director TitleAgeSince
Director/Board Member 69 01/02/2008
Chairman 71 01/05/2023
Director/Board Member 76 01/12/2012
Change 5d. change 1-year change 3-years change Capi.($)
-0.83%-3.60%-2.23%+45.35% 2.47B
+1.11%+2.91%-18.21%-43.95% 2.26B
-4.55%-13.64%+61.08%+56.55% 1.97B
-7.73%+7.87%+12.12%-32.73% 1.52B
-3.38%-4.01%+276.39% - 858M
-3.83%-12.34%-14.67%+83.01% 822M
+2.36%+6.94%+1.49%-3.82% 743M
+0.34%+1.46%-10.07%-8.31% 707M
-1.29%+4.07%+67.76%-77.61% 449M
+5.24%-8.35% - - 429M
Average -1.26%-0.88%+41.52%+2.31% 1.22B
Weighted average by Cap. -1.85%-1.62%+28.93%+9.02%

Financials

2026 *2027 *
Net sales 577M 491M 455M 428M 797M 53.62B 814M 5.33B 2.09B 25.75B 2.16B 2.12B 91.74B 648M 552M 511M 481M 896M 60.24B 914M 5.99B 2.34B 28.93B 2.43B 2.38B 103B
Net income 75.05M 63.94M 59.17M 55.71M 104M 6.98B 106M 694M 272M 3.35B 282M 276M 11.94B 92.34M 78.67M 72.8M 68.55M 128M 8.59B 130M 854M 334M 4.12B 347M 339M 14.69B
Net Debt -523M -446M -412M -388M -723M -48.66B -738M -4.84B -1.89B -23.36B -1.96B -1.92B -83.25B -666M -568M -525M -495M -921M -61.96B -940M -6.16B -2.41B -29.76B -2.5B -2.45B -106B
Logo Veracyte, Inc.
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Employees
755
Date Price Change Volume
10/04/26 31.09 $ -0.83% 798,488
09/04/26 31.35 $ -4.04% 510,432
08/04/26 32.67 $ +1.62% 826,015
07/04/26 32.15 $ -0.53% 504,866
06/04/26 32.32 $ +0.22% 411,763
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
31.09USD
Average target price
47.00USD
Spread / Average Target
+51.17%

Quarterly revenue - Rate of surprise